Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 14/20 | 0.76 |
| ▸ | PSMB2 | P49721 | 5/20 | 0.76 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.76 |
| ▸ | PSMB10 | P40306 | 3/20 | 0.76 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.76 |
| ▸ | PSMB9 | P28065 | 3/20 | 0.76 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.76 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.76 |
| ▸ | PSMD12 | O00232 | 1/20 | 0.76 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.76 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.76 |
| ▸ | PSMD3 | O43242 | 1/20 | 0.76 |
| ▸ | CTSB | P07858 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | PSMC3 | P17980 | 1/20 | 0.76 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.76 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.76 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.76 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.76 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8280662 | 1.00 | PSMB5 (0.76) | PSMB5PSMB2PSMB8PSMB10PSMB1 | |
| SCHEMBL18871907 | 1.00 | PSMB5 (0.76) | PSMB5PSMB2PSMB8PSMB10PSMB1 | |
| SCHEMBL20284322 | 0.93 | PSMB5 (0.76) | PSMB5PSMB2PSMB8PSMB10PSMB1 | |
| SCHEMBL17750784 | 0.93 | PSMB5 (0.76) | PSMB5PSMB2PSMB8PSMB10PSMB1 | |
| SCHEMBL20284324 | 0.93 | PSMB5 (0.76) | PSMB5PSMB2PSMB8PSMB10PSMB1 | |
| SCHEMBL21035432 | 0.93 | PSMB5 (0.76) | PSMB5PSMB2PSMB8PSMB10PSMB1 | |
| SCHEMBL18835529 | 0.92 | PSMB5 (0.75) | PSMB5PSMB2PSMB8PSMB10PSMB1 | |
| SCHEMBL13742992 | 0.92 | PSMB5 (0.75) | PSMB5PSMB2PSMB8PSMB10PSMB1 | |
| SCHEMBL18835528 | 0.92 | PSMB5 (0.75) | PSMB5PSMB2PSMB8PSMB10PSMB1 | |
| SCHEMBL2633254 | 0.91 | PSMB5 (0.73) | PSMB5PSMB2PSMB8PSMB10PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136085-A1 | TARGETED THERAPEUTICS | TVA (ABC), LLC | 2017-05-18 | — | — | US | disclosed |
| US-8324174-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120277146-A1 | Compounds For Enzyme Inhibition | ONYX PHARMACEUTICALS INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8207124-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207126-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207127-B2 | Compounds for enzyme inhibition | ONYX TECHNOLOGIES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207125-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207297-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120101050-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101048-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8129346-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-7491704-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491704-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080200398-A1 | Compounds For Enzyme Inhibition | PROTEOLIX, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200398-A1 | Compounds For Enzyme Inhibition | PROTEOLIX, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7232818-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232818-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| WO-2005105827-A2 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200398-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | PSMB5 24/4885PSMB2 14/4885PSMB8 46/4885 |
| US-20170136085-A1 | TARGETED THERAPEUTICS | HSP90B1, HSP90AB1, CDC37 | PSMB5 1248/4885PSMB2 1729/4885PSMB8 1540/4885 |
| US-20120101048-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | PSMB5 24/4885PSMB2 14/4885PSMB8 46/4885 |
| US-20120101050-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | PSMB5 24/4885PSMB2 14/4885PSMB8 46/4885 |
| US-20120277146-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | PSMB5 24/4885PSMB2 14/4885PSMB8 46/4885 |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, PSMB1 | PSMB5 21/4885PSMB2 11/4885PSMB8 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.